基本分析
透過季節調整季營收，判斷美股整體趨勢，但注意股價有時候領先基本面的數據，應搭配其他領先指標判斷。
基本資料
個股的基本資料，以及所屬的類股和產業。
公司介紹
業務介紹
瑞迪實驗室有限公司及其子公司在全球範圍內運營一家綜合性製藥公司。它通過全球仿製藥、製藥服務和活性成分(PSAI)、專有產品和其他業務部門經營。該公司的全球仿製藥業務部門生產和銷售處方藥和非處方成品藥品,這些產品以品牌名稱或具有與品牌配方療效等同的仿製成品形式銷售。該部門還從事生物製劑業務。PSAI部門生產和銷售活性藥物成分和中間體,這些是成品藥品的主要成分。該部門還提供合同研究服務;並根據客戶的具體要求生產和銷售活性藥物成分和類固醇。其專有產品部門專注於差異化配方的研發。其他部門從事腫瘤學和炎症領域的療法開發。主要治療類別包括胃腸道、心血管、抗糖尿病、皮膚科、腫瘤學、呼吸系統、口腔科、泌尿科和腎科。該公司與Curis, Inc.有合作、許可和期權協議,以發現、開發和商業化免疫腫瘤學和精準腫瘤學靶點的小分子拮抗劑。瑞迪實驗室有限公司於1984年註冊成立,總部位於印度海得拉巴。
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
警語
1. 資料僅供參考，不做任何獲利保證及特定股票與點位推薦建議。
2. 資料並不完整，需要完整資料請至相關網站索取。
3. 任何股市數據分析皆存在倖存者偏差。
